| 1A | 1B | 1C | 1D | 1E | 1F | 1G | 2A | 2B | 2C | 2D | 3A | 3B | 3C | 3D | 4A | 5A | 5B |
1A | No data | No data | No data | Seizures | 100.0% | Alpers syndrome | 50.0% | Developmental Delay | 50.0% | Hepatopathy | 50.0% | Neuropathy | 50.0% | Other | 50.0% | in a total of 2 patients |
| No data | No data | No data | Unknown | 100.0% | in 1 patient |
| No data | No data | No data | No data | No data | No data | No data | No data | No data | No data |
1B | | No data | No data | Developmental Delay | 75.0% | Seizures | 75.0% | GI symptoms | 50.0% | Hypotonia | 50.0% | Other | 50.0% | Ataxia | 25.0% | in a total of 4 patients |
| No data | No data | No data | Ataxia | 100.0% | CPEO | 100.0% | Developmental Delay | 100.0% | Migraines | 100.0% | Myopathy | 100.0% | Neuropathy | 100.0% | in 1 patient |
| No data | No data | No data | No data | | No data | No data | No data | No data | Ataxia | 100.0% | CNS symptoms | 100.0% | CPEO | 100.0% | Neuropathy | 100.0% | Other | 100.0% | in 1 patient |
|
1C | | | No data | No data | CPEO | 100.0% | CNS symptoms | 50.0% | Myopathy | 50.0% | in a total of 2 patients |
| No data | No data | Developmental Delay | 100.0% | Ataxia | 75.0% | Seizures | 75.0% | Alpers syndrome | 25.0% | GI symptoms | 25.0% | Hepatopathy | 25.0% | in a total of 4 patients |
| No data | No data | No data | No data | No data | No data | No data | No data | No data | Seizures | 100.0% | in 1 patient |
|
1D | | | | Unknown | 100.0% | in 1 patient |
| Ataxia | 66.7% | Seizures | 66.7% | CNS symptoms | 33.3% | Developmental Delay | 33.3% | Migraines | 33.3% | Myopathy | 33.3% | in a total of 3 patients |
| CNS symptoms | 100.0% | CPEO | 100.0% | Myopathy | 100.0% | Ataxia | 50.0% | Developmental Delay | 50.0% | Neuropathy | 50.0% | in a total of 2 patients |
| No data | Seizures | 87.5% | Developmental Delay | 62.5% | Alpers syndrome | 53.1% | Hepatopathy | 37.5% | Ataxia | 28.1% | Hypotonia | 25.0% | in a total of 32 patients |
| No data | CPEO | 77.8% | Myopathy | 55.6% | Neuropathy | 33.3% | Ataxia | 22.2% | Developmental Delay | 22.2% | Other | 22.2% | in a total of 9 patients |
| No data | Ataxia | 50.0% | CNS symptoms | 50.0% | CPEO | 50.0% | Myopathy | 50.0% | Seizures | 50.0% | in a total of 2 patients |
| Alpers syndrome | 50.0% | Ataxia | 50.0% | CPEO | 50.0% | Developmental Delay | 50.0% | Migraines | 50.0% | Myopathy | 50.0% | in a total of 2 patients |
| No data | Developmental Delay | 57.1% | Ataxia | 42.9% | CPEO | 42.9% | Alpers syndrome | 28.6% | GI symptoms | 28.6% | Hepatopathy | 28.6% | in a total of 7 patients |
| Hypotonia | 100.0% | Developmental Delay | 66.7% | Other | 66.7% | CPEO | 33.3% | GI symptoms | 33.3% | Hepatopathy | 33.3% | in a total of 3 patients |
| Ataxia | 80.0% | CNS symptoms | 80.0% | CPEO | 60.0% | Migraines | 40.0% | Other | 40.0% | Developmental Delay | 20.0% | in a total of 5 patients |
| Seizures | 77.8% | Developmental Delay | 59.3% | Alpers syndrome | 48.1% | Hepatopathy | 44.4% | Ataxia | 33.3% | CNS symptoms | 18.5% | in a total of 27 patients |
|
1E | | | | | Myopathy | 60.0% | CPEO | 40.0% | Hepatopathy | 40.0% | Ataxia | 20.0% | CNS symptoms | 20.0% | Developmental Delay | 20.0% | in a total of 5 patients |
| No data | Developmental Delay | 100.0% | GI symptoms | 100.0% | Hepatopathy | 100.0% | Hypotonia | 100.0% | in 1 patient |
| Developmental Delay | 87.5% | Seizures | 83.3% | Alpers syndrome | 45.8% | Hepatopathy | 33.3% | Hypotonia | 16.7% | Other | 16.7% | in a total of 24 patients |
| CPEO | 100.0% | Myopathy | 100.0% | Neuropathy | 100.0% | in 1 patient |
| CPEO | 100.0% | Myopathy | 100.0% | Neuropathy | 100.0% | Other | 50.0% | in a total of 2 patients |
| No data | Ataxia | 100.0% | CNS symptoms | 100.0% | in 1 patient |
| No data | No data | Ataxia | 66.7% | Developmental Delay | 66.7% | Seizures | 66.7% | Alpers syndrome | 33.3% | CNS symptoms | 33.3% | CPEO | 33.3% | in a total of 3 patients |
| No data | Alpers syndrome | 100.0% | Ataxia | 100.0% | Developmental Delay | 100.0% | Seizures | 100.0% | in 1 patient |
| Seizures | 58.3% | Developmental Delay | 41.7% | Hepatopathy | 41.7% | Ataxia | 33.3% | Myopathy | 33.3% | CPEO | 25.0% | in a total of 12 patients |
|
1F | | | | | | No data | No data | CPEO | 75.0% | Myopathy | 62.5% | CNS symptoms | 50.0% | Hepatopathy | 25.0% | Neuropathy | 25.0% | Ataxia | 12.5% | in a total of 8 patients |
| Developmental Delay | 100.0% | Hepatopathy | 100.0% | Other | 100.0% | in 1 patient |
| CPEO | 50.0% | Developmental Delay | 50.0% | GI symptoms | 50.0% | Hepatopathy | 50.0% | Hypotonia | 50.0% | Myopathy | 50.0% | in a total of 2 patients |
| No data | No data | No data | No data | No data | No data | No data | Ataxia | 50.0% | CNS symptoms | 50.0% | Hepatopathy | 50.0% | Hypotonia | 50.0% | Neuropathy | 50.0% | Seizures | 50.0% | in a total of 2 patients |
|
1G | | | | | | | No data | Developmental Delay | 75.0% | Alpers syndrome | 50.0% | Hypotonia | 50.0% | Seizures | 50.0% | CPEO | 25.0% | Hepatopathy | 25.0% | in a total of 4 patients |
| Developmental Delay | 100.0% | Myopathy | 100.0% | in 1 patient |
| CPEO | 50.0% | Neuropathy | 50.0% | GI symptoms | 33.3% | Hepatopathy | 33.3% | Other | 33.3% | Ataxia | 16.7% | in a total of 6 patients |
| No data | No data | No data | Developmental Delay | 100.0% | Hepatopathy | 100.0% | Hypotonia | 100.0% | in 1 patient |
| Developmental Delay | 100.0% | GI symptoms | 100.0% | Neuropathy | 100.0% | in 1 patient |
| CPEO | 50.0% | Developmental Delay | 50.0% | GI symptoms | 50.0% | Hypotonia | 50.0% | Myopathy | 50.0% | Other | 50.0% | in a total of 2 patients |
| No data | Ataxia | 100.0% | CNS symptoms | 50.0% | CPEO | 50.0% | Developmental Delay | 50.0% | Hypotonia | 50.0% | Myopathy | 50.0% | in a total of 2 patients |
|
2A | | | | | | | | Ataxia | 67.4% | Seizures | 65.2% | CNS symptoms | 54.3% | CPEO | 54.3% | Neuropathy | 47.8% | Myopathy | 26.1% | in a total of 46 patients |
| Ataxia | 100.0% | CNS symptoms | 100.0% | CPEO | 100.0% | Myopathy | 100.0% | in 1 patient |
| CPEO | 55.6% | Developmental Delay | 55.6% | Seizures | 44.4% | Alpers syndrome | 33.3% | Ataxia | 33.3% | CNS symptoms | 22.2% | in a total of 9 patients |
| Ataxia | 100.0% | Developmental Delay | 50.0% | Hepatopathy | 50.0% | Myopathy | 50.0% | Neuropathy | 50.0% | Other | 50.0% | in a total of 2 patients |
| CPEO | 100.0% | Ataxia | 50.0% | CNS symptoms | 50.0% | Myopathy | 50.0% | in a total of 2 patients |
| Seizures | 62.5% | CNS symptoms | 43.8% | Developmental Delay | 43.8% | CPEO | 31.3% | Alpers syndrome | 25.0% | Myopathy | 25.0% | in a total of 16 patients |
| Developmental Delay | 100.0% | Hepatopathy | 100.0% | Hypotonia | 50.0% | in a total of 2 patients |
| CPEO | 75.0% | Developmental Delay | 75.0% | GI symptoms | 75.0% | Hepatopathy | 75.0% | Myopathy | 50.0% | Neuropathy | 50.0% | in a total of 4 patients |
| Developmental Delay | 100.0% | Seizures | 100.0% | GI symptoms | 66.7% | Hypotonia | 66.7% | Neuropathy | 33.3% | Other | 33.3% | in a total of 3 patients |
| CPEO | 83.3% | Ataxia | 66.7% | CNS symptoms | 50.0% | Myopathy | 50.0% | Other | 33.3% | Developmental Delay | 16.7% | in a total of 6 patients |
| Ataxia | 80.9% | CPEO | 57.4% | Seizures | 46.8% | CNS symptoms | 44.7% | Neuropathy | 44.7% | Migraines | 27.7% | in a total of 47 patients |
|
2B | | | | | | | | | No data | No data | No data | No data | No data | No data | No data | No data | No data | No data |
2C | | | | | | | | | | CPEO | 80.0% | Myopathy | 50.0% | Neuropathy | 30.0% | Developmental Delay | 20.0% | GI symptoms | 20.0% | Other | 20.0% | in a total of 10 patients |
| No data | No data | CPEO | 100.0% | Myopathy | 75.0% | Ataxia | 25.0% | CNS symptoms | 25.0% | in a total of 4 patients |
| CPEO | 100.0% | CNS symptoms | 50.0% | Myopathy | 25.0% | Neuropathy | 25.0% | in a total of 4 patients |
| Ataxia | 100.0% | CNS symptoms | 100.0% | CPEO | 100.0% | Myopathy | 100.0% | in 1 patient |
| Developmental Delay | 60.0% | Alpers syndrome | 40.0% | CPEO | 40.0% | Hepatopathy | 40.0% | Hypotonia | 40.0% | Seizures | 40.0% | in a total of 5 patients |
| | CNS symptoms | 50.0% | CPEO | 50.0% | in a total of 2 patients |
|
2D | | | | | | | | | | | CNS symptoms | 100.0% | CPEO | 100.0% | Myopathy | 100.0% | in 1 patient |
| No data | No data | No data | No data | No data | Developmental Delay | 100.0% | Hepatopathy | 100.0% | Hypotonia | 100.0% | in 1 patient |
| Seizures | 100.0% | Hepatopathy | 66.7% | Alpers syndrome | 33.3% | Developmental Delay | 33.3% | Myopathy | 33.3% | in a total of 3 patients |
|
3A | | | | | | | | | | | | CNS symptoms | 100.0% | CPEO | 100.0% | in 1 patient |
| No data | No data | No data | No data | No data | No data |
3B | | | | | | | | | | | | | CPEO | 90.0% | Myopathy | 70.0% | Neuropathy | 60.0% | Hepatopathy | 40.0% | Ataxia | 30.0% | CNS symptoms | 30.0% | in a total of 10 patients |
| No data | Developmental Delay | 100.0% | Seizures | 100.0% | Alpers syndrome | 50.0% | Ataxia | 50.0% | CNS symptoms | 50.0% | CPEO | 50.0% | in a total of 2 patients |
| No data | Alpers syndrome | 50.0% | Ataxia | 50.0% | Developmental Delay | 50.0% | Neuropathy | 50.0% | Seizures | 50.0% | in a total of 2 patients |
| CPEO | 100.0% | Myopathy | 66.7% | CNS symptoms | 33.3% | Developmental Delay | 33.3% | Hepatopathy | 33.3% | Migraines | 33.3% | in a total of 3 patients |
|
3C | | | | | | | | | | | | | | No data | No data | No data | CNS symptoms | 66.7% | CPEO | 66.7% | Ataxia | 33.3% | Myopathy | 33.3% | Unknown | 33.3% | in a total of 3 patients |
| Developmental Delay | 100.0% | GI symptoms | 100.0% | Hepatopathy | 100.0% | Seizures | 100.0% | in 1 patient |
|
3D | | | | | | | | | | | | | | | Developmental Delay | 75.0% | Seizures | 62.5% | Alpers syndrome | 50.0% | Hepatopathy | 37.5% | Hypotonia | 12.5% | Myopathy | 12.5% | in a total of 8 patients |
| No data | CPEO | 75.0% | Ataxia | 50.0% | CNS symptoms | 50.0% | Alpers syndrome | 25.0% | Developmental Delay | 25.0% | Other | 25.0% | in a total of 4 patients |
| Seizures | 100.0% | CPEO | 50.0% | Developmental Delay | 50.0% | Hepatopathy | 50.0% | Myopathy | 50.0% | Neuropathy | 50.0% | in a total of 2 patients |
|
4A | | | | | | | | | | | | | | | | No data | No data | Hepatopathy | 50.0% | Seizures | 50.0% | Alpers syndrome | 25.0% | Ataxia | 25.0% | CNS symptoms | 25.0% | Developmental Delay | 25.0% | in a total of 4 patients |
|
5A | | | | | | | | | | | | | | | | | Ataxia | 100.0% | CNS symptoms | 100.0% | CPEO | 100.0% | Myopathy | 100.0% | in 1 patient |
| Seizures | 50.0% | Unknown | 50.0% | in a total of 2 patients |
|
5B | | | | | | | | | | | | | | | | | | Ataxia | 91.0% | CNS symptoms | 76.1% | Seizures | 61.2% | CPEO | 53.7% | Neuropathy | 37.3% | Migraines | 22.4% | in a total of 67 patients |
|
|
| 1A | 1B | 1C | 1D | 1E | 1F | 1G | 2A | 2B | 2C | 2D | 3A | 3B | 3C | 3D | 4A | 5A | 5B |